GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (STU:8BT) » Definitions » Current Deferred Revenue

BriaCell Therapeutics (STU:8BT) Current Deferred Revenue : €0.00 Mil (As of Jan. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BriaCell Therapeutics Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

BriaCell Therapeutics's current deferred revenue for the quarter that ended in Jan. 2024 was €0.00 Mil.

BriaCell Therapeutics Current Deferred Revenue Historical Data

The historical data trend for BriaCell Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Current Deferred Revenue Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BriaCell Therapeutics Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (STU:8BT) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

BriaCell Therapeutics (STU:8BT) Headlines

No Headlines